Cecilia Nasso

Savona, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study).

Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study).

Journal: Minerva urology and nephrology

Published: April 23, 2026

Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) study.

Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) study.

Journal: Frontiers in immunology

Published: February 26, 2026

Patterns of first-line treatment selection in metastatic renal cell carcinoma: a real-world analysis from the Meet-URO 33-REGAL study.

Patterns of first-line treatment selection in metastatic renal cell carcinoma: a real-world analysis from the Meet-URO 33-REGAL study.

Journal: Therapeutic advances in medical oncology

Published: January 26, 2026

Concomitant medications and survival outcomes in patients receiving avelumab maintenance for advanced urothelial carcinoma: sub analysis of Meet-URO 25 study.

Concomitant medications and survival outcomes in patients receiving avelumab maintenance for advanced urothelial carcinoma: sub analysis of Meet-URO 25 study.

Journal: Clinical genitourinary cancer

Published: January 14, 2026

Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 study.

Effectiveness of ICI-ICI versus ICI-TKI combinations in patients with IMDC intermediate- and poor-risk metastatic renal cell carcinoma: a sub-analysis of the MEET-URO 33 study.

Journal: Cancer immunology, immunotherapy : CII

Published: October 24, 2025

Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort.

Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort.

Journal: European urology open science

Published: October 16, 2025

Site and number of metastases predict outcomes in avelumab maintenance for advanced UC: results from meet-URO 25.

Site and number of metastases predict outcomes in avelumab maintenance for advanced UC: results from meet-URO 25.

Journal: Cancer immunology, immunotherapy : CII

Published: October 14, 2025

Real-world effectiveness of Avelumab maintenance in advanced urothelial carcinoma: results from the Italian multicenter MALVA study (Meet-URO 25).

Real-world effectiveness of Avelumab maintenance in advanced urothelial carcinoma: results from the Italian multicenter MALVA study (Meet-URO 25).

Journal: The oncologist

Published: June 06, 2025

Immune checkpoint inhibitors in gynecological cancers: a narrative review on the practice-changing trials.

Immune checkpoint inhibitors in gynecological cancers: a narrative review on the practice-changing trials.

Journal: Immunotherapy

Published: February 02, 2025

Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations.

Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations.

Journal: Immunotherapy

Published: January 20, 2025

Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study.

Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study.

Journal: Targeted oncology

Published: September 01, 2024

A Novel Molecular Profile of Hormone-Sensitive Prostate Cancer Defines High Risk Patients.

A Novel Molecular Profile of Hormone-Sensitive Prostate Cancer Defines High Risk Patients.

Journal: Cancer medicine

Published: July 08, 2024

Showing 1-12 of 29

Last Updated: 09/26/2026